价格

NK cell therapy

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIK AND THERAPY
- EP 2287195 B1
  申请人: NOVO NORDISK AS优先权: 2004
  CN
  EP
  US
  13 件公开
- CN 1852924 A
  申请人: INNATE PHARMA优先权: 2003
  CN
TISSUE FACTOR-TARGETING CAR-NK AND CAR-T CELL THERAPY
EP 3687555 A4申请人: OHIO STATE INNOVATION FOUNDATION优先权: 2017
CN
EP
US
WO
5 件公开
Modified NK-92 cells, and therapeutic and diagnostic uses thereof
US 12606608 B2申请人: UNIV DER JOHANNES GUTENBERG UNIV MAINZ优先权: 2019
EP
US
WO
5 件公开
PDL1 POSITIVE NK CELL CANCER TREATMENT
EP 3989984 A4申请人: HOPE CITY优先权: 2019
CN
EP
US
WO
4 件公开
METHODS AND USES OF USING ACTIVATORS OF NRF2 TO ENHANCE NATURAL KILLER CELLS AND/OR T CELL ACTIVITY AND/OR SURVIVAL
EP 4373477 A2申请人: PROLEUKOCYTE AB优先权: 2021
CN
EP
US
WO
4 件公开
CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO B-CELL MATURE ANTIGEN (BCMA) AND/OR TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR (TACI)
EP 4590329 A2申请人: ELPIS BIOPHARMACEUTICALS优先权: 2022
CN
EP
US
WO
4 件公开
IMPROVED NK-BASED CELL THERAPY
EP 3551294 A1申请人: ONKIMMUNE LTD优先权: 2016
CN
EP
US
4 件公开
NATURAL KILLER (NK) CELLS EXPRESSING AN ANTIGEN-SPECIFIC FUNCTIONAL T CELL RECEPTOR (TCR) COMPLEX, METHODS FOR PRODUCTION THEREOF, AND METHODS FOR THERAPEUTIC USE THEREOF
EP 3565565 A4申请人: UNIV NOVA SOUTHEASTERN优先权: 2017
EP
US
WO
4 件公开
PURIFYING TCR-MODIFIED T CELLS USING TCR-SPECIFIC CAR-NK CELLS
US 20260130994 A1申请人: UNIV BERLIN CHARITE优先权: 2022
EP
US
WO
4 件公开
Compositions and methods for regulating NK cell activity
US 2006280740 A1申请人: NOVO NORDISK AS优先权: 2006
US
4 件公开

药物

NK cell therapy

专利

PAN-KIR2DL NK-RECEPTOR ANTIBODIES AND THEIR USE IN DIAGNOSTIK AND THERAPY